Delayed Graft Function (DGF) in Kidney Transplantation – Comprehensive Study Notes

Objectives of the Module

Understand delayed graft function (DGF) as a manifestation of acute kidney dysfunction unique to transplantation.
Review definitions, incidence, pathophysiology, risk factors, diagnosis, biomarkers, clinical impact, preventive strategies, treatments, and knowledge gaps.

Definitions of DGF

>>10< separate definitions exist in the literature.
- Examples:
- Change (Δ) in serum creatinine (Scr) or glomerular filtration rate (GFR).
- Absolute Scr or GFR cut-offs.
- Urine‐output criteria (e.g., oliguria).
Most widely adopted operational definition → need for dialysis within $7$ days post-transplant.
- Chosen because it is simple, auditable, and enables inter-center comparison, despite recognized limitations (center-dependent dialysis thresholds, potential confounders).

Incidence

Registry data (last decade):
- Deceased-donor kidneys: ≈ $25\%$ develop DGF.
- Living-donor kidneys: $3$ – $5\%$ develop DGF.
Despite technological & immunological advances, incidence has remained unchanged.

Historical vs. Contemporary Pathophysiology

Classic paradigm: ischemia → acute tubular necrosis (ATN).
Modern view: multifactorial “injury cascade.”
- Brain death (DBD)–induced micro-vascular spasm & systemic inflammation begin hours before retrieval.
- Up-regulation of endothelial adhesion molecules → thrombosis + leukocyte recruitment.
- Cold storage → further endothelial damage & cellular swelling.
- Reperfusion → burst of reactive oxygen species (ROS) + activation of innate/adaptive immunity.
- Persistent injury ⇒ interstitial fibrosis & tubular atrophy (IF/TA).

Donor after Cardiac Death (DCD) Kidneys

Highest DGF rate due to additional warm ischemia during circulatory stand-off.
- Cortical reperfusion → perivascular edema → sustained ischemia at the cortico-medullary junction.
- “Micro-vascular no-reflow” in the medulla; prolonged duration ↑ risk of primary non-function (PNF).

Living Donation

DGF rate in single digits.
Pathogenesis likely related to:
- High intra-abdominal pressure.
- Graft traction & reflex vasoconstriction.
Minimal cerebral inflammatory component → explains limited long-term impact on graft survival.

Technical / Surgical Contributors

Retrieval technique & kidney laterality ≈ neutral when done by experienced teams.
Extraction time > $60$ min → odds ratio $1.19$ per extra $5$ min for DGF.

Risk Factors for DGF

Donor Factors

Donor type: DCD > DBD > Living.
Prolonged brain death (≥ $24$ h) & ICU stay (≥ $40$ h).
Marginal quality (high Kidney Donor Risk Index / Kidney Donor Profile Index).
Female donors with rising Scr, acute kidney injury (AKI).
Preservation method (static cold vs. machine perfusion).

Recipient Factors

Long dialysis vintage & wait-time (single greatest contributor).
Obesity, diabetes mellitus, older age, African-American ethnicity, male sex.
Sensitized patients (high PRA).
Small donor-to-recipient size ratio.

Diagnostic Work-up (Diagnosis of Exclusion)

Monitor urine output, Scr trend, fluid status, drug levels.
If dysfunction persists > $7$ – $10$ days → renal allograft biopsy.
- Repeat biopsy every $1$ – $2$ weeks if DGF persists (silent rejection up to $17\%$ ).
Biopsy picture in pure DGF: ATN or minimal change.
Rule out/treat alternative causes: acute rejection, obstruction, vascular thrombosis, drug toxicity, infection, recurrence of primary disease.

Emerging Biomarkers

Goal: predict DGF within hours of reperfusion.
Most studied markers:
- Neutrophil gelatinase–associated lipocalin (NGAL).
- Interleukin- $18$ (IL- $18$ ).
Multicenter prospective cohort ( $n=91$ deceased-donor recipients):
- Groups: DGF ( $n=34$ ) vs. slow graft function (SGF, $n=33$ ) vs. immediate graft function (IGF, $n=24$ ).
- NGAL & IL- $18$ in urine separated the three groups at all early time-points.
- Elevated early NGAL/IL- $18$ predicted DGF & correlated with recovery up to $3$ months.

Clinical Impact of DGF

Graft Survival:
- Meta-analysis ( $21$ studies, mean follow-up $3.2$ y) → relative risk (RR) of graft loss with DGF $=1.41$ .
- SRTR analysis ( > $80{\,}000$ deceased-donor transplants, $1998$ – $2006$ ): $13.5\%$ ↑ risk of censored graft failure at $1$ y.
- Need for multiple dialysis sessions → worse outcomes vs. single session.
Acute Rejection (AR):
- Ischemia-reperfusion injury up-regulates allo-immune cascades.
- Modern analyses show DGF increases long-term graft failure independent of AR.
Chronic Rejection / IF-TA: emerging single-center links; mechanism still under investigation.
Patient Survival: conflicting; recent large registries suggest DGF ↑ long-term mortality; earlier meta-analyses (pre- $2007$ ) did not.
Healthcare Utilization: longer hospitalization & higher cost.

Prevention & Mitigation Strategies

Donor Management

Hemodynamic & metabolic donor management goals (DMGs) pre-procurement:
- MAP, CVP, EF, pH, Na⁺, glucose, temp, urine output.
Study ( $n=722$ kidneys from $492$ DBD donors):
- Early achievement of DMGs at time of consent (only $14\%$ achieved) → protective.

Procurement Technique

Prompt cold perfusion & rapid organ extraction (< $60$ min ideal).
Ensure full surface ice contact (kidneys ≈ last organs & prone to warm injury).

Preservation Modality

Hypothermic pulsatile machine perfusion (HMP) vs. static cold storage (SCS):
- International paired-kidney RCT ( $336$ donors): HMP ↓ DGF across all donor subtypes & ↓ discard, esp. extended-criteria donor (ECD) kidneys.
Ex-vivo normothermic perfusion: experimental; technology & portability barriers.

Intra-operative Recipient Care

Maintain euvolemia; CVP ≥ $8$ cm H₂O reduces DGF without pulmonary compromise.

Immunosuppression Modulation

Induction Therapy
- General use of induction ↓ DGF rates.
- Prospective RCT: intra-operative rabbit ATG vs. delayed ( $6$ h post-reperfusion):
  - DGF $14.8\%$ vs. $35.5\%$ , lower Scr.
- Agent choice:
  - Historical equivalence between rATG & IL-2R antagonists (basiliximab).
  - Recent data (modern rATG dosing $6$ – $7.5$ mg/kg) suggest rATG advantage; ongoing RCT.
  - Alemtuzumab (CAMPATH) shows no difference vs. rATG / IL-2R antagonists.
Maintenance Therapy
- Calcineurin inhibitors (CNI) = vasoconstrictive.
- Early CNI avoidance/minimization has not convincingly lowered DGF and may ↑ early AR risk.

Post-operative Supportive Care

Adequate perfusion pressure & avoidance of nephrotoxins.
Monitor & correct electrolyte/acid-base derangements.
Dialysis as needed (standard HD vs. CRRT based on hemodynamics).
Serial biopsies for persistent DGF.

Treatment: Current Reality

No targeted pharmacologic cure exists.
Management = supportive + preventive.

Key Knowledge Gaps & Future Directions

Validation & real-time integration of urinary/serum biomarkers (NGAL, IL- $18$ , KIM- $1$ , L-FABP, etc.).
Optimization of normothermic ex-vivo perfusion protocols.
Personalized immunosuppression algorithms balancing ischemic injury & rejection risk.
Longitudinal studies linking early biomarker profile → chronic IF-TA & patient survival.

Summary “Take-Home” Points

DGF affects ≈ $1$ in $4$ deceased-donor kidney recipients; incidence has not improved.
Pathogenesis = multifactorial ischemia-reperfusion & immune injury; DCD kidneys highest risk.
DGF independently predicts graft loss, acute rejection, longer stay, and possibly mortality.
Diagnosis requires exclusion of other causes; serial biopsy & emerging biomarkers aid early detection.
Preventive opportunities span donor management, surgical technique, machine perfusion, intra-operative hydration, and timely induction IS.
No definitive treatment—goal is damage minimization & graft support.